Bicara Therapeutics Inc. (BCAX) stock
BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.75−0.27 (-2.69%)
Close on Nov 16, 2026Market cap $645.19MP/E –Yield –
Bicara Therapeutics cash
Cash and short-term investments held at the end of each period.
Bicara Therapeutics's cash was $442.35M at Sep 30, 2026. For fiscal 2025 it was $414.80M, down 15.3% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $414.80M | -15.3% |
| FY2024 | Dec 31, 2024 | $489.71M | +112.5% |
| FY2023 | Dec 31, 2023 | $230.44M | +5442.1% |
| FY2022 | Dec 31, 2022 | $4.16M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $442.35M | +52.4% |
| Q2 FY2026 | Jun 30, 2026 | $497.26M | +13.9% |
| Q1 FY2026 | Mar 31, 2026 | $539.75M | +16.8% |
| Q4 FY2025 | Dec 31, 2025 | $414.80M | -15.3% |
| Q3 FY2025 | Sep 30, 2025 | $290.17M | -44.3% |
| Q2 FY2025 | Jun 30, 2025 | $436.61M | +114.2% |
| Q1 FY2025 | Mar 31, 2025 | $462.07M | +113.9% |
| Q4 FY2024 | Dec 31, 2024 | $489.71M | +112.5% |
| Q3 FY2024 | Sep 30, 2024 | $520.76M | +1077.9% |
| Q2 FY2024 | Jun 30, 2024 | $203.86M | +4802.7% |
| Q1 FY2024 | Mar 31, 2024 | $216.05M | – |
| Q4 FY2023 | Dec 31, 2023 | $230.44M | – |
| Q3 FY2023 | Sep 30, 2023 | $44.21M | – |
| Q4 FY2022 | Dec 31, 2022 | $4.16M | – |
See a number that looks wrong?